Abstract
Recent studies have identified the osteoblast as an insulin responsive cell that participates in global energy homeostasis. Here, we show that glucose transporter-4 (Glut4) is required for insulindependent uptake and oxidation of glucose in mature osteoblasts. In primary cultures of mouse osteoblasts, insulin increased uptake and oxidation of 14C-glucose in a dose-dependent fashion but did not significantly affect uptake or oxidation of 14C-oleate. In vitro, undifferentiated osteoblasts expressed 3 high-Affinity Gluts: Glut1, Glut4, and Glut3. However, although levels of Glut1 and Glut3 remained constant during the course of osteoblast differentiation, Glut4 expression increased by 5-fold in association with enhanced insulin-stimulated glucose uptake. Glut4 ablation in osteoblasts in vitro eliminated insulin-stimulated glucose uptake, reduced proliferation and diminished measures of osteoblast maturation. In vivo, Glut4 expression was observed in osteoblasts, osteocytes, and chondrocytes at a level approaching that observed in adjacent skeletal muscle. To determine the importance of Glut4 in bone in vivo, we generated mice lacking Glut4 in osteoblasts and osteocytes (δGlut4). δGlut4 mice exhibited normal bone architecture but exhibited an increase in peripheral fat in association with hyperinsulinemia, β-cell islet hypertrophy, and reduced insulin sensitivity. Surprisingly, the expression of insulin target genes in liver, muscle, and adipose from δGlut4 mice were unchanged or increased, indicating that alterations in glucose homeostasis were the result of reduced clearance by bone. These findings suggest that Glut4 mediates insulin-stimulated glucose uptake by mature osteoblasts/osteocytes and that the magnitude of glucose use by bone cells is sufficient to impact global glucose disposal in the mouse.
Original language | English |
---|---|
Pages (from-to) | 4094-4103 |
Number of pages | 10 |
Journal | Endocrinology |
Volume | 157 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2016 |
Bibliographical note
Publisher Copyright:Copyright © 2016 by the Endocrine Society.
Funding
This work was supported by the Merit Review Grant BX001234 from the Biomedical Laboratory Research and Development Service of the Veterans Affairs Offi ce of Research and Development (to T.L.C.) and by National Institutes of Health Grants DK099134 (to R.C.R.), NS072241 (to M.J.W.), and DK093000 (to J.K.K.). T.L.C. is a recipient of a Research Career Scientist Award from the Department of Veterans Affairs . Support was also provided by the Johns Hopkins University-University of Maryland Diabetes Research Center Grant DK079637. Disclosure Summary: The authors have nothing to disclose.
Funders | Funder number |
---|---|
Johns Hopkins University-University of Maryland Diabetes Research Center | DK079637 |
National Institutes of Health (NIH) | DK099134, NS072241, DK093000 |
National Institutes of Health (NIH) | |
U.S. Department of Veterans Affairs | I01BX001234 |
U.S. Department of Veterans Affairs | |
Biomedical Laboratory Research and Development, VA Office of Research and Development |
ASJC Scopus subject areas
- Endocrinology